<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03921203</url>
  </required_header>
  <id_info>
    <org_study_id>ApoB48IC2</org_study_id>
    <nct_id>NCT03921203</nct_id>
  </id_info>
  <brief_title>ApoB48 Metabolism in Plasma and Interstitial Fluid</brief_title>
  <official_title>ApoB48IC2 Metabolism in Plasma and Interstitial Fluid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postprandial increases in the levels of atherogenic chylomicron remnant lipoprotein particles
      have long been considered a presumable risk factor for the development of atherosclerosis
      with time, also in normolipidemic subjects. apoB-48 (Chylomicron) in blood is a specific
      marker for intestinal derived lipoproteins. Specific aim: To determine if apoB-48 containing
      lipoproteins may appear in IC in the postprandial state after a standard meal and investigate
      the effect fasting and feeding have on levels of lipids, apolipoproteins and the cholesterol
      component of lipoproteins in IF and plasma.

      Methodology: Intercellular fluid will be collected using the cup technique. IF will be
      collected in intervals corresponding to different periods after food intake. The IF from
      these different occasions will then be analysed and compared using FPLC and Elisa.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 17, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>ApoB48 levels in blood and interstitial fluid</measure>
    <time_frame>7 hours</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Type 2 diabetes patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Interstitial fluid and blood (serum, plasma and whole blood)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy controls and type 2 diabetes patients over 18 years old, matched for age and
        gender.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Over 18 years.

          -  For the T2D study group: Diagnosed with type 2 diabetes.

        Exclusion Criteria:

        For subjects with type 2 diabetes:

          -  Systemic inflammatory disease that requires active treatment

          -  Thyroid disease that requires active treatment

          -  Skin disease that requires active treatment and causes significant changes in the area
             of the skin that is to be investigated

          -  Treatment with oral glucocorticoids

          -  Levels of SR, TSH, T4 or Hemoglobin in the blood pronouncedly outside the reference
             range

          -  Pregnancy

        For healthy controls:

          -  Registered disease in the health declaration that requires continuous systemic
             treatment. Exception to the above: well controlled hypertension in which case the
             subject should not have treatment with more than one antihypertensive drug, the drug
             must not be an alpha-blocker or beta-blocker or thiazide diuretic

          -  Skin disease that requires active treatment and causes significant changes in the area
             of the skin that is to be investigated

          -  Blood pressure pronouncedly above 140/90

          -  Blood test results pronouncedly outside the reference range

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mats Rudling</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mats Rudling</last_name>
    <phone>+46 8585 869 55</phone>
    <email>mats.rudling@ki.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Patient research centre, Clinic of endocrinology, Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <state>Huddinge</state>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Viveca Ã…berg</last_name>
      <email>viveca.aberg@ki.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 17, 2019</study_first_submitted>
  <study_first_submitted_qc>April 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2019</study_first_posted>
  <last_update_submitted>April 17, 2019</last_update_submitted>
  <last_update_submitted_qc>April 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Mats Rudling</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

